Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can ginger boost a hunger hormone linked to Parkinson's?

NCT ID NCT07882108

Knowledge-focused Sponsor: Cambridge University Hospitals NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 20, 2026 · Last updated Oct 22, 2026 · Updated 2 times

Summary

Researchers are testing whether ginger supplements can raise levels of ghrelin, a hunger hormone that tends to be lower in people with Parkinson's disease and REM sleep behavior disorder. The study includes people with Parkinson's, people with REM sleep behavior disorder, and healthy adults of similar age. Participants take ginger capsules for 12 weeks at one of two doses. The main goal is to see if ginger causes a dose-related increase in blood ghrelin levels. Secondary goals include checking whether ginger reduces inflammation, improves gut symptoms like constipation, and is well tolerated.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ginger root extract capsules
What this could lead to
If ginger raises ghrelin levels, it could support a larger trial testing whether ginger helps slow or modify Parkinson's disease.
What could go wrong
This is an early, small study with 72 participants. It may not show a clear effect, and ginger could cause digestive side effects or interact with other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

People with PD * 55 years of age or above; * Meet Movement Disorder Society criteria for Idiopathic PD People with RBD * 55 years of age or above; * RBD diagnosis confirmed by polysomnography; * Prodromal PD probability score of 80% or above on the Movement Disorders Society calculator. Controls • 55 years of age or above.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation Parkinson disease REM sleep behavior disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease Rem sleep behavior disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Cambridge

    RECRUITING

    Cambridge, CB2 0PY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.